ONCOBIX

ONCOBIX is working toward developing innovative therapies for rare and incurable diseases with challenging treatments... Non-small cell lung cancer (NSCLC), which accounts for 85% of lung cancer cases worldwide, has been on an upward trend since 2000 due to air pollution, chemical products, and genetic mutations. Notably, 10-15% of all lung cancer patients have developed resistance to conventional drugs and now suffer without standard treatment. With our own platform technology, ONCOBIX aims to overcome this resistance to currently available treatments. We have established pipelines to study and develop globally competitive fourth-generation drugs for NSCLC and pulmonary fibrosis. Our promise is to contribute to the health and well-being of humanity, delivering a better quality of life and longevity to patients suffering from diseases... We strive to grow as a drug discovery company specializing in identifying and developing candidates with potential as new global drugs.

Also known as: ONCOBIX Inc.

Registration numbers: 534-86-00661 (W)

Primary location: Seoul South Korea